Prior to joining Disarm Therapeutics he was Chief Scientific Officer of Padlock Therapeutics until its acquisition by BMS in March 2016. Raj previously served as President and Chief Executive Officer of Euclises Pharmaceuticals and Senior Vice President of Deciphera Pharmaceuticals. Before that time, he was Senior Vice President of Jubilant Drug Discovery & Development and held positions of increasing leadership responsibility with Pfizer Global R&D and legacy Pharmacia and Searle companies. He has led discovery & early clinical development teams that have advanced multiple candidates into clinical trials for refractory cancers, rheumatoid arthritis, diabetic nephropathy, COPD, and pain. Raj has BS in Pharmacy and received his PhD in Medicinal Chemistry from Duquesne University.

Jeff’s research laboratory uses genomic and metabolic approaches to understand the process by which unhealthy or injured axons degenerate, an early pathologic event that underlies most neurodegenerative diseases and peripheral neuropathies. His lab has made major discoveries including identification and characterization of the GDNF neurotrophic factor family whose members are being developed into treatments for neurological disorders, and the molecular link between metabolism, NAD and axon health. He holds over 25 patents on neurotrophic factors, axonal protective agents, and their use in treating neurological disorders.

Jeff graduated from Washington University Medical School (WUSM, MD, 1978) and the University of Virginia (UVA, PhD, 1983). He completed his residency in Pathology at UVA and joined the Departments of Pathology and Medicine at WUSM in 1983. He became the David Clayson Professor of Neurology in 2005 and the Head of the Department of Genetics in 2009. Under his leadership, the Department is focusing on disease-based genetic research and helping WUSM become an international leader in Precision Medicine and Genome Engineering.

For almost 40 years, Steven has sought to understand the causes and treatments of peripheral neuropathies, and has developed a focus on inherited neuropathies. He sees people who have neuropathy in his clinics, and his laboratory efforts are focused on neuropathy, too. He has served on NIH Study Section, on the medical board of the CMT Association, and is the current president of the Peripheral Nerve Society. He has taught/mentored undergraduate, medical and graduate students, residents, fellows, and has served on 44 thesis committees. Steven is an author on 143 original research papers and 69 reviews.

Bruce is Chairman of the Department of Neurosciences at the Lerner Research Institute, Cleveland Clinic, Professor of Neurosciences at Case Western Reserve University and a fellow of the American Association for the Advancement of Science (AAAS). He joined the Cleveland Clinic as Chairman of the Department of Neurosciences in 1994. His research investigates the cause of neurological disability in multiple sclerosis patients, cellular mechanism of brain repair in neurodegenerative diseases, and the molecular biology of myelination in the central and peripheral nervous systems.  He is internationally known for his work on mechanisms of neurodegeneration and repair in multiple sclerosis and has published over 240 peer-reviewed articles and over 30 book chapters. Bruce is a member of the advisory board of major biotech companies, the National Institutes of Health and the National Multiple Sclerosis Society. He is active in organizing national and international conferences related to Neurodegenerative diseases.

Bruce is the recipient of the Jordi Folch-Pi Award, the Award of the American Society of Neurochemistry, The Weil Award from the American Association of Neuropathologists, the Harry Weaver Neuroscience Scholar Award from the National Multiple Sclerosis Society (NMSS), the Jacob Javits Award in Neuroscience from the National Institute of Neurological Disorders and Stroke, the John Dystel Prize for MS Research from the American Academy of Neurology and the National Multiple Sclerosis Society, the Scientific Achievement Award in Basic Science and the Award for Excellence in Science from the Cleveland Clinic.

He received his PhD from Loyola University Stritch School of Medicine in Chicago, IL and postdoctoral training at the National Institutes of Health (NIH), Bethesda, MD. He then was appointed Assistant and subsequently Associate Professor of Neurology at the Johns Hopkins University School of Medicine in Baltimore. 

Prior to joining Disarm, Todd held positions at Alkermes and Boehringer-Ingelheim. Most recently he led a medicinal chemistry effort that delivered a drug candidate to proceed into clinical trials. He contributed to the molecular discovery and lead optimization of several other development candidates for immunology, inflammation and cardiometabolic indications. He is the author of over 30 patents and peer-reviewed publications.

Todd earned his PhD in organic chemistry at the University of Pittsburgh and was an NIH postdoctoral fellow with Amos B. Smith, III at the University of Pennsylvania.